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Abstract
Objective—To evaluate whether HIV-1 clade C (HIV-C) envelope variations that arise during
disease progression in rhesus macaque model reflect changes that occur naturally in human infection.
Design—An infant macaque was infected with SHIV-1157i, an R5 tropic clade C SHIV (SHIV-C)
which expresses a primary HIV-C envelope derived from an infected human infant, and monitored
over a five-year period. Genetic variation of the V1-V5 envelope region, which is the main target
for humoral immune responses, derived from the infected macaque and infant was examined.
Methods—V1-V5 envelope region were cloned and sequenced from longitudinal PBMC samples
collected from the infected macaque and infant. Phylogenetic analysis (phylogenetic tree, diversity,
divergence, ratio of non-synonymous (dN) and synonymous substitution (dS) and dN distribution)
were performed. Plasma RNA viral load, CD4+ T-cell count, changes in the length of V1-V5 region,
putative N-linked glycosylation sites (PNGSs) number and distribution were also measured.
Results—Phylogenetic analysis revealed that changes in the macaque closely reflected those of
infant during disease progression. Similar distribution patterns of dN and hot spots were observed
between the macaque and infant. Analysis of PNGSs revealed several common variations between
the virus populations in the two host species. These variations correlate with decline of CD4 count
in the macaque and might be linked with disease progression.
Conclusion—SHIV-C infection of macaque is a relevant animal model for studying variation of
primary HIV-C envelope during disease progression and could be used to analyze the selection
pressures that are associated with those changes.
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Introduction
The V1-V5 region of HIV-1 envelope glycoprotein is the focus of numerous studies due to its
critical role in viral pathogenesis and immune evasion [1–7]. Because of its hyper-variable
nature, majority of the potential vaccines targeting the envelope have thus far failed to elicit
sterilizing immunity against heterologous viral challenge in animal studies and human clinical
trials [8–14]. Thus, it is important to better understand the changes of V1-V5 region that occur
during the course of disease and the factors that contribute to these changes.
Non-human primate models that utilize SHIV [15–20] had been used to study clade B and
laboratory-adapted strain envelope variants during the course of disease [21–23]. It has been
suggested that there is a close similarity in the envelope evolution during SHIV infection of
non-human primates and HIV-1 infection of humans; similar envelope mutations were
observed over time in a laboratory worker accidentally infected with HIV-1 IIIB and a macaque
experimentally infected with a SHIV expressing the identical envelope [22,24]. However,
HIV-1 IIIB is an X4 laboratory-adapted clade B virus whose envelope evolution may not be
representative of that of R5 tropic primary isolates and only a small number of sequences from
both the macaque and human were analyzed. Several studies have also indicated that the env
of different HIV-1 clades can evolve differently under selective pressure [1,25,26]. To
adequately determine if SHIV infection of macaques is a viable model for assessing envelope
evolution, SHIV constructs using env from recently transmitted and biologically relevant,
primary HIV-1 isolates must be tested. The evolutionary biology of the R5 SHIV-C in this
current study, SHIV-1157i, represents such a virus.
We have been following a cohort of mostly HIV-C infected mother/infant pairs in Lusaka,
Zambia. Among them, infant 1157i, a slow-progressor, was followed prospectively and viruses
derived longitudinally from the infant have been extensively characterized [27]. SHIV-1157i
was generated with an R5 tropic env derived from infant 1157i at 6 months old. An infant
macaque was infected with SHIV-1157i and monitored through disease progression until it
died from AIDS after ~5 years [28,29]. Over this period, we tracked the changes of V1-V5
region from the time of inoculation to euthanasia of the infected macaque. Together with data
previously gathered for infant 1157i, we were able to compare the genetic variation of the V1-
V5 region of this particular primary clade C isolate during disease progression in both species
[27].
Since our study utilized a clade C primary R5 tropic env instead of an X4 laboratory-adapted
clade B strain, and we analyzed over 300 viral envelope sequences, our investigation represents
a more in depth comparison of viral evolution during disease progression. This study has
provided a unique opportunity to identify potential envelope mutations in the infected macaque
which may associate with and predict future disease progression in the infected infant.
Methods
Construction of SHIV-1157i
SHIV-1157i contains env of a primary HIV-C isolate from a 6 month old Zambian infant 1157i.
PuvI (P) was introduced into the 3′ half of SHIV-vpu+ proviral DNA. The 2.0-kb KpnI (K)-
PvuI fragment of HIV1157i was amplified to replace the corresponding region of SHIV-vpu
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+ env. The modified 3′ half was ligated with the 5′ half of SHIV-vpu+ proviral DNA to form
full-length SHIV-1157i (Fig. 1A) [28,29].
Animals and animal care
An infant Indian rhesus macaque (Macaca mulatta), RPn-8, was inoculated intravenously with
6 ml cell-free supernatant from 293T cells transfected with the infectious molecular clone,
SHIV-1157i, and followed prospectively with complete blood counts, T-cell subset analyses,
viral RNA load determinations, and clinical exams [28]. This animal was kept according to
National Institutes of Health guidelines on the care and use of laboratory animals at the Yerkes
National Primate Research Center (YNPRC). The facility is fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care International. All experiments
were approved by the Animal Care and Use Committees of the YNPRC and the Dana-Farber
Cancer Institute.
Plasma viral RNA load
RNA was isolated from plasma using QiaAmp Viral Mini Kit (Qiagen), and vRNA loads were
measured by quantitative reverse transcriptase PCR for SIV gag sequences [30]. The detection
limit was 50 viral RNA copies/ml of plasma [28].
PCR, cloning and sequencing
Sample collection, cloning and sequencing of infant 1157i V1-V5 env region have been
described previously [27,31]. Genomic DNA of infected macaque PBMC was extracted from
6, 20, 37, 50 and 64 months post-inoculation samples using Genomic DNA Purification Kit
(Gentra Systems). Nested PCR was used to amplify a 1.1 kb fragment spanning the V1-V5
env region. First round PCR was performed with the primers ENF1 (5′
GATGCATGAGGATATAATCAGTTTATGGGA 3′) and ENR1 (5′
ATTGATGCTGCGCCCATAGTGCT 3′). Second round PCR was performed with the primers
1157i-DraIII (5′ TTGACTCCACTCTGTGTCACTTTAAAG 3′) and 1157i-AvrII-AS (5′
TGCTATTCCTAGGGGCTTGATTTCTAC 3′). To minimize PCR bias, first round PCR
products were generated in duplicates and combined to be used as templates for the second
round PCR. Amplified fragments were cloned into pSP72 NL4-3 A-S-Av after digestion with
Dra III and Avr II and sequenced with dideoxy terminators (ABI BigDye Kit).
Sequence analyses
Sequence alignment was carried out on the translated amino-acid sequence in ClustalW [32],
as implemented in BioEdit 7.0.9.0. Neighbor-joining phylogenetic analyses were done in
MEGA using the Kimura 2-parameter distance to explore genealogical relationships among
infant 1157i and macaque RPn-8 V1-V5 sequences, and support for the nodes was evaluated
with bootstrap.
Variations in genetic diversity, genetic divergence, the number and location of putative N-
linked glycosylation sites (PNGSs), and the length of the V1-V5 fragment were analyzed. Viral
genetic diversity was estimated as the average nucleotide difference between sequences within
a contemporaneous set, and genetic divergence was calculated as the average genetic distance
to the earliest viral population collected for the human or macaque, respectively. The number
and location of PNGSs was estimated using N-GlycoSite from the Los Alamos National
Laboratory.
The instantaneous rates of nonsynonymous (dN) and synonymous substitutions (dS) were
compared to evaluate the role of natural selection. Estimates of dN, dS, and dN/dS for each
time point were obtained in Datamonkey using the Fixed Effects Likelihood procedure [33].
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Results
HIV-1157i and SHIV-1157i infection courses
The HIV-C V1-V5 region used to construct SHIV-1157i was derived from a cloned viral isolate
of infant 1157i obtained at 6 months old. This child was infected in-utero, delivered naturally
with normal birth weight and breast-fed till 20 months old. Both the child and his mother were
anti-retroviral drug naïve. Infant 1157i is designated as a slow-progressor since he remains
clinically asymptomatic throughout the study period, with a CD4+ T-cell count of 811 cells/ul
at ~8 years old. Analyses of viral isolates from this infant have been published previously
[27], and the viral sequences are included here for comparison.
SHIV-1157i was constructed as described (Fig. 1A) [29] and inoculated intravenously into the
infant macaque RPn-8. Systemic infection was achieved after inoculation with a plasma viral
RNA load of ~3.7 x 104 copies/ml detected at 2 weeks post inoculation (pi) and remained at
~1.0 x 104 copies/ml or higher for most of the study period (Fig. 1B). CD4+ T-cells steadily
declined over time, reaching <200 cells/ul at ~28 months pi (Fig. 1C) and remained low till
euthanasia at 64 months pi due to AIDS, as characterized by opportunistic infections [28].
PBMC were collected longitudinally throughout the study and samples from 6, 20, 37, 50 and
64 months pi were selected for this study. The V1-V5 region was cloned and sequenced. A
total of 161 V1-V5 env clones were obtained from all time points, ~32 clones per time point.
Phylogenetic relationship among V1-V5 sequences from macaque and human
The neighbor-joining phylogeny clustered all envelope sequences derived from the infected
macaque in a monophyletic clade (Fig. 2), consistent with the fact that they all derived from a
single infectious molecular clone, SHIV-1157i. Both the macaque and infant portions of the
tree resemble the idealized trees expected for viruses evolving under continuous immune
pressure [34]. Sequences collected at later time points concentrated on the longer branches of
the tree. The distribution of sequences from later time points indicates that the phylogenetic
structure of the tree is more complicated in the infant than in the macaque. Infant sequences
from the 67-month time point are scattered throughout the tree, with some sequences clustered
with earlier lineages. In contrast, all macaque sequences from the last time point were found
in a monophyletic clade.
Longitudinal variation in diversity and divergence
Constraints within the viral env may hamper certain amino acid changes, regardless of any
unique selective pressure by the individual host species, because of the cost to replicative fitness
of the virus. As such, env changes we observed in infant 1157i during viral evolution may be
similarly reflected in the macaque. To determine whether longitudinal variation of the V1-V5
region in isolates from RPn-8 and 1157i have similarities, we compared changes in the diversity
and divergence of all viral populations sampled from each host. Viral genetic diversity
measures the level of polymorphism found within a viral population at the nucleotide level,
whereas divergence measures the differentiation of a population relative to the original strain.
In the case of macaque, divergence was calculated relative to the sequence of the single clone
inoculated experimentally, whereas in the infant, divergence was calculated as the average
genetic distance between all sequences within the viral population at a given time point and
all sequences from the viral population at birth.
Our results indicate that diversity and divergence followed similar trajectories in both the
macaque and infant at early time points but differ at later time points (Fig. 3A & B). In the case
of infant, diversity increased quasi-monotonically over time, reaching an average pair-wise
distance of 4.3% at 67 months after birth. Diversity in the macaque increased in parallel with
the infant for the first 20 months. Thereafter, diversity gradually leveled off, reached its peak
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of an average genetic distance of 2.8% in the population collected 50 months pi, and decreased
slightly at the time of euthanasia (Fig. 3A).
Sequence divergence in the infant increased in parallel with its diversity until it reached its
maximum of 3.6% at 48 months. This was ensued by a noticeable decrease to 2.7% at 67
months. This decrease in divergence coincided with the re-emergence of viral lineages derived
from earlier sequences shown by our phylogenetic results. Interestingly, divergence in the
macaque increased monotonically throughout the study, and reached 3.7% by 64 months pi
(Fig. 3B).
Synonymous and non-synonymous changes in macaque and human
To evaluate the role played by natural selection, we compared the ratio of dN/dS (Fig. 3C).
Briefly, dN/dS ratios are expected to be ~0 under strong purifying selection, ~1 under neutrality,
and >1 in cases where positive Darwinian selection is the major evolutionary force driving
variation in the gene studied. In the infant, the dN/dS ratio was >1 in the majority of the
populations sampled, ranging from 0.97 at 6 months to 1.44 at 67 months of age. In contrast,
the dN/dS ratio in the macaque remained <1 till 50 months pi where it declined to 0.52. These
data suggest that selective pressure was stronger in the infant than in the macaque. We then
compared the distribution of these changes in the viral populations from the infant and macaque
by plotting the number of observed dN per codon per time point (Fig. 3D). The comparison
shows that despite the differences in the number of changes and selective pattern, amino acid
replacements accumulated in similar regions in the infant and macaque. These regions include
the variable loops as well as in the supposedly conserved C3 and C4 regions.
Longitudinal changes in the number of N-linked glycosylation sites in V1-V5
It has been suggested that lengthening of the V1-V5 region and an increase in PNGSs correlate
with slower disease progression [3,21]. To see if this held true in our study, we examined the
change in number of PNGSs in RPn-8 and found that it declined over time from 26 PNGSs
present in the inoculum to a mean of 21 PNGSs by 37 months pi (Table 1). This was followed
by a gradual recovery to a mean of 25 PNGSs by 64 months pi. The V1-V5 length in RPn-8
followed a similar trend (Table 1). In contrast to the macaque, variation in PNGSs and V1-V5
length in the infant showed no directional pattern.
In both the macaque and infant, the majority of the PNGSs were distributed in identical regions.
With 17 PNGSs in RPn-8 and 14 PNGSs in 1157i that were relatively conserved throughout
the infection (Fig. 4A). These conserved PNGSs may have important roles in the structural
integrity or receptor binding capability of envelope. However, differences in PNGS do exist
between the macaque and infant. The macaque had only 9 PNGSs that were variable throughout
the infection, compared with 12 PNGSs in the infant. Interestingly, 6 of these variable sites
(N56, 100, 165, 208, 324 and 327) were identical between the macaque and infant.
The temporal dynamics of the variations in PNGSs were similar for both the infant and
macaque. For instance, sites N100, 208, 324 and 327 fluctuated in both 1157i and RPn-8 over
time. For site N56, changes in the infant were observed starting from 6 months. In comparison
with the macaque, the identical PNGS was ablated at 37 months but gradually reemerged by
64 months pi. Another site with similar changes between 1157i and RPn-8 is N165. Prevalence
of the PNGS at N165 reached its lowest level by 36 months old in the infant before remerging.
Likewise, this site was reduced in the macaque at 20 months but, contrary to the infant, this
PNGS was completely ablated by 37 months pi and never reemerged from later time points in
the macaque. We also noticed a pattern unique to the macaque, where the prevalence of several
PNGSs, including N56, was reduced near 37 month pi but gradually re-emerged at later time
points.
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Discussion
In the present study, we analyzed changes in the V1-V5 envelope region in viral populations
sampled longitudinally from an R5 SHIV-C infected macaque with those from a Zambian
infant. Longitudinal variation in sequence diversity and divergence in HIV-1 infection in
humans has been intensely studied, and we found that SHIV infection in this macaque followed
the general pattern described for HIV-1 infection in humans [35]: an initial phase where both
diversity and divergence increased linearly up to the 20 month sampling interval; an
intermediate phase where diversity stabilized but divergence continued to increase up to the
50 month sampling interval; a late phase where divergence and diversity decreased or stabilized
from the 50 month sample onwards. Our sampling intervals did not allow us to precisely
determine the time transitions between the different phases.
In humans naturally infected with HIV-1, differential rates of disease progression have been
linked with viral genetic diversity and dN/dS ratios. In particular, higher dN/dS estimates
appear to correlate with slower rates of disease progression, as is the case for having a higher
number of sites inferred to be evolving under positive Darwinian selection or having high
adaptation rates [36,37]. Estimates of genetic diversity and dN/dS were all higher in the infant,
a slow progressor, which is in agreement with previous observations [38–40]. These data
suggests that ablation of the macaque’s immune responses at later time points resulted in a
drastic reduction of selective pressure on the viral populations. In comparison, the infant’s
immune status appears to be healthy and exert a significant selective pressure on the viral
populations, in fact, the child remains asymptomatic at age 10.
The distribution of dN along the V1-V5 region for the infant and macaque was located primarily
within the variable loops. But our analysis also indicated an unexpected variable domain
located in the α2-helix of C3 in the infant and macaque viruses. Alterations within this domain
correlate with low CD4 counts in the macaque, suggesting that it may contain an immune
epitope and could affect the biological properties of the virus [41–45]. This phenomenon could
be clade specific, as the homologous region is reported to be more conserved in clade B [1,
25,41,46]. As reported by other groups, emergence of deletions within V4 was also observed
in the infant and macaque in this study (Fig. 4B) [22,24,47].
N-glycosylation plays a critical role in immune evasion, and increases in the number of PNGS
have been linked with immune resistance [2,7,48,49]. Although we found no clear pattern of
change for the number of PNGSs in the infant, we did observed an interesting pattern of
decreasing PNGSs after inoculation and a gradual recovery at later time points in the macaque.
Reductions of PNGSs number in the macaque between 6 and 37 months pi coincide with its
rapid decline in CD4 count and the onset of AIDS. Whether the eventual recovery of PNGSs
at the last time point is due to immune escape or increase in replication fitness is unclear
[50–53].
Besides sharing similar PNGS distribution patterns and hot spots, we observed several similar
PNGS variations within viral populations of the infant and macaque. In particular, N56 that
locates at the C-terminal of V2, and N165 that locates within C2. Alteration of PNGS at the
C-terminal of V2 has been reported in animals infected by clade B SHIV [21,22,54]. A recent
study also demonstrated that removal of PNGS at this position increases HIV-1 89.6 sensitivity
to neutralizing antibodies [55], thus suggesting that N56 could be a common immunological
epitope for both clade B and C viruses [56,57]. It is surprising to find a variable PNGS, N165,
within a constant region in the infant and macaque. Changes at this site coincide with the
macaque’s persistently low CD4 counts and were shown by others to affect the virus sensitivity
to monoclonal antibodies [29,58]. Ablation of a similar site has also been reported in patients
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[7]. It is possible that N165 is an immune epitope and ablation of it might enhance the infectivity
or kinetics of the escape viruses.
In order to eliminate the possibility that any of the clones were the result of in-vitro PCR
recombination, phylogenetic analyses were performed to distinguish between PCR
recombination and actual in-vivo recombination events. Briefly, with in-vivo recombination
one would observe an accumulation of mutations after a recombination event on a given branch
within an estimated phylogeny. However, with PCR recombination there would be no such
additional substitutions on the recombinant branch and therefore the clones would be non-
unique and identical to parental clones. Application of this test revealed a negligible number
of clones were indeed generated by PCR recombination. In fact, only two and four clones,
respectively, were identified for the macaque and infant that showed no additional substitutions
along a branch in the estimated phylogeny (data not shown). Thus, PCR recombination
occurred on a minor scale and did not adversely affect our analyses. Limiting dilution PCR
(LDPCR) was not feasible in this study due to insufficient materials for most of the time points
analyzed. Nevertheless, LDPCR was carried out on the last time point sampled of the macaque
and revealed clones with similar phylogenetic distributions that were consistent with those
obtained by the regular PCR approach. No inherent differences were observed between the
two procedures.
Taken together, our data suggest that genetic evolution of an R5 SHIV generated from the
envelope of a primary isolate reflects changes that occur in HIV-1 during disease progression
in the infected infant. The infected macaque has a relatively faster disease progression in
comparison with the infant, but a much slower disease progression compare with other SHIVs
such as SHIV89.6P. This could be due to the differences in selection forces between the two
species. Our data also imply that these changes occur in a compressed time frame since the
infected macaque progressed to AIDS while the child has remained asymptomatic. Although
there is no identical individual amino acid mutation comparable with previously reported clade
B studies, mutations do seem to occur in similar regions. In addition, even though it is difficult
to make a direct comparison of the time course between human and macaque in disease
progression, mutations observed in our infected macaque at later time points could be indicators
of future disease progression in the child. A further understanding of factors which caused
these genetic changes could provide beneficial insights for future HIV-1 vaccine designs, and
the significance of these changes on the biological function of the envelope is currently under
investigation. The caveat for our study is the small sample size and the observation may be
limited to this human and macaque pair. However, this is a prospective study and the first study
to our knowledge demonstrating the evolutionary similarity of a primary clade C envelope
between a naturally infected human with an experimentally infected macaque. This study also
re-enforces the previous observation that HIV-1 envelope undergoes similar changes in human
and monkey during disease progression [22].
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Fig. 1.
(A). Pvu I (P) was introduced into the 3′ half of SHIV-vpu+ (28) proviral DNA. The 2.0 Kb
Kpn I - Pvu I fragment of HIV-1 1157i (spanning most of gp120 as well as the entire gp41
extracellular domain and the transmembrane region [TM]) was amplified to replace the
corresponding region in the SHIV-vpu+ envelope. The modified 3′ half of SHIV-vpu+ was
ligated with the 5′ half of SHIV-vpu+ proviral DNA to form the full length SHIV-1157i [28,
29]. (B) Plasma viral RNA load and (C) absolute CD4+ T-cell counts.
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Fig. 2.
Consensus tree from a Neighbor-Joining bootstrap analysis showing phylogenetic relationships
among viral samples derived from the longitudinal follow-up of the macaque (RPn-8, solid
lines) and infant (1157i, dashed lines) in this study. Labels indicate the source and time of
sample collection. For example, RPn-8 20M corresponds to viral sequences coming from the
macaque, and collected 20 months post-inoculation. Cut-off value for the condensed tree was
set at 75%.
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Fig. 3.
Changes in (A) genetic diversity and (B) divergence over time for infant 1157i and macaque
RPn-8. Genetic diversity is calculated from the average number of nucleotide differences
within a given time point. Genetic divergence is calculated from the average number of changes
between each time point and the initial population. (C) non-synonymous and synonymous (dN/
dS) ratio over time for infant 1157i and macaque RPn-8. (D) Estimated number of observed
non-synonymous substitutions per codon within V1-V5 region in infant 1157i and macaque
RPn-8. Results represented are cumulative of all time points for human or macaque. M
represents either months of age in human or months post inoculation in macaque. Numbers of
the horizontal axis correspond to amino acid position within the sequence alignment. All
variable loops and constant regions within the alignment are labeled.
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Fig. 4.
(A) V1-V5 consensus sequence of infant 1157i at 0 month of age and inoculation strain
SHIV-1157i is shown. Putative N-linked glycosylation sites (PNGSs) within sequences from
all time points were located as described in Methods. n represents relatively conserved PNGSs
in macaque or human over time. N represents variable PNGSs in macaque or human over time.
Common variable PNGSs between macaque and human are circled. Variable regions and
constant regions are shown along the bottom of the sequences. (B) sequence alignment of V4
in infant 1157i and macaque RPn-8 at different time points. Sequences were aligned using
Bioedit 7.0.9.0. Sequences represented here are examples from each time points. These are not
consensus sequences and do not represent all observed variations within V4.
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